AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
balsalazide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| phenylazosalicylic acid derivatives antibacterial | 284 | 80573-04-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 6.75 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 269.86 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 87 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 77 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKA,AURKB,AURKC,AXL,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK16,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FGFR1,GRK2,GRK3,IKBKB,JAK2,MAP2K3,MAP2K6,MAP3K14,MAP3K2,MAP3K7,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,MTOR,PIK3CB,PIK3CD,PIM3,PLK1,PLK2,PLK3,PLK4,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,UHMK1,ULK1,ULK2 | 54 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 18, 2000 | FDA | SALIX PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Effusion | 56.05 | 34.11 | 10 | 591 | 2052 | 90625794 |
| Colitis ulcerative | 55.06 | 34.11 | 19 | 582 | 60247 | 90567599 |
| Congestive cardiomyopathy | 48.75 | 34.11 | 11 | 590 | 7343 | 90620503 |
| Left ventricular dysfunction | 36.51 | 34.11 | 10 | 591 | 14659 | 90613187 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Lactobacillus infection | 66.80 | 36.72 | 10 | 522 | 364 | 42620439 |
| Subacute endocarditis | 63.97 | 36.72 | 8 | 524 | 72 | 42620731 |
| Bacterial translocation | 61.23 | 36.72 | 10 | 522 | 643 | 42620160 |
| Gastrointestinal bacterial infection | 46.73 | 36.72 | 8 | 524 | 683 | 42620120 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Colitis ulcerative | 54.49 | 30.28 | 22 | 992 | 77341 | 110510944 |
| Subacute endocarditis | 51.19 | 30.28 | 7 | 1007 | 181 | 110588104 |
| Effusion | 49.88 | 30.28 | 10 | 1004 | 2747 | 110585538 |
| Lactobacillus infection | 44.07 | 30.28 | 7 | 1007 | 513 | 110587772 |
| Bacterial translocation | 43.02 | 30.28 | 8 | 1006 | 1484 | 110586801 |
| Congestive cardiomyopathy | 37.98 | 30.28 | 11 | 1003 | 14208 | 110574077 |
| Gastrointestinal bacterial infection | 37.06 | 30.28 | 7 | 1007 | 1411 | 110586874 |
| Left ventricular dysfunction | 32.54 | 30.28 | 11 | 1003 | 23482 | 110564803 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A07EC04 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFLAMMATORY AGENTS Aminosalicylic acid and similar agents |
| FDA CS | M0000971 | Aminosalicylic Acids |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| FDA EPC | N0000175781 | Aminosalicylate |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:50266 | prodrug |
Related Drugs by ATC class:
A07EC Aminosalicylic acid and similar agents 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ulcerative colitis | indication | 64766004 | DOID:8577 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Pyloric obstruction | contraindication | 244815007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.28 | acidic |
| pKa2 | 4.08 | acidic |
| pKa3 | 11.45 | acidic |
| pKa4 | 12.18 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GIAZO | VALEANT PHARMS INTL | N022205 | Feb. 3, 2012 | DISCN | TABLET | ORAL | 9192616 | Aug. 2, 2026 | TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS |
| 750MG | COLAZAL | VALEANT PHARMS INTL | N020610 | July 18, 2000 | RX | CAPSULE | ORAL | 7452872 | Aug. 24, 2026 | TREATMENT OF ULCERATIVE COLITIS |
| 750MG | COLAZAL | VALEANT PHARMS INTL | N020610 | July 18, 2000 | RX | CAPSULE | ORAL | 7625884 | Aug. 24, 2026 | TREATMENT OF ULCERATIVE COLITIS |
| 1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GIAZO | VALEANT PHARMS INTL | N022205 | Feb. 3, 2012 | DISCN | TABLET | ORAL | 7452872 | Aug. 24, 2026 | TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS |
| 1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GIAZO | VALEANT PHARMS INTL | N022205 | Feb. 3, 2012 | DISCN | TABLET | ORAL | 7625884 | Aug. 24, 2026 | TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS |
| 1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GIAZO | VALEANT PHARMS INTL | N022205 | Feb. 3, 2012 | DISCN | TABLET | ORAL | 8497256 | June 23, 2031 | TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
| Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
| Arachidonate 5-lipoxygenase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Enzyme | IC50 | 5.41 | CHEMBL | |||||
| Nucleoside diphosphate kinase, mitochondrial | Enzyme | EC50 | 4.34 | CHEMBL | |||||
| Glutaryl-CoA dehydrogenase, mitochondrial | Enzyme | EC50 | 4.76 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021231 | VUID |
| N0000148675 | NUI |
| D02715 | KEGG_DRUG |
| 150399-21-6 | SECONDARY_CAS_RN |
| 153718 | RXNORM |
| C0052940 | UMLSCUI |
| CHEBI:267413 | CHEBI |
| BLQ | PDB_CHEM_ID |
| CHEMBL1201346 | ChEMBL_ID |
| CHEMBL1200760 | ChEMBL_ID |
| DB01014 | DRUGBANK_ID |
| C038637 | MESH_SUPPLEMENTAL_RECORD_UI |
| 54585 | PUBCHEM_CID |
| 11569 | IUPHAR_LIGAND_ID |
| 5221 | INN_ID |
| P80AL8J7ZP | UNII |
| 130137 | MMSL |
| 15641 | MMSL |
| 37855 | MMSL |
| 37856 | MMSL |
| 5056 | MMSL |
| d01031 | MMSL |
| d04700 | MMSL |
| C0127615 | UMLSCUI |
| DB00244 | DRUGBANK_ID |
| 4075 | PUBCHEM_CID |
| 4019494 | VANDF |
| 4021231 | VANDF |
| 4021232 | VANDF |
| 001600 | NDDF |
| 007156 | NDDF |
| 007157 | NDDF |
| 387501005 | SNOMEDCT_US |
| 391811002 | SNOMEDCT_US |
| 420306005 | SNOMEDCT_US |
| 420557005 | SNOMEDCT_US |
| 86977007 | SNOMEDCT_US |
| CHEBI:6775 | CHEBI |
| P80AL8J7ZP | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0079 | CAPSULE | 750 mg | ORAL | ANDA | 23 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-102 | CAPSULE | 750 mg | ORAL | ANDA | 24 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-820 | CAPSULE | 750 mg | ORAL | ANDA | 23 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6137 | CAPSULE | 750 mg | ORAL | ANDA | 25 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-2575 | CAPSULE | 750 mg | ORAL | ANDA | 24 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-209 | TABLET | 1.10 g | ORAL | ANDA | 21 sections |
| balsalazide disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1626 | CAPSULE | 750 mg | ORAL | ANDA | 24 sections |
| balsalazide disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1841 | CAPSULE | 750 mg | ORAL | ANDA | 24 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72162-2095 | CAPSULE | 750 mg | ORAL | ANDA | 23 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72789-149 | CAPSULE | 750 mg | ORAL | ANDA | 23 sections |
| Balsalazide Disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72789-149 | CAPSULE | 750 mg | ORAL | ANDA | 23 sections |
| balsalazide disodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 80005-126 | CAPSULE | 750 mg | ORAL | ANDA | 24 sections |